|
A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction |
Valgimigli M, Mittmann N, Cohen D J, Campo G, Isogai P K, Seung S J, Dulisse B, Arcozzi C, Squasi P, Percoco G, Ferrari R |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Valgimigli M, Mittmann N, Cohen D J, Campo G, Isogai P K, Seung S J, Dulisse B, Arcozzi C, Squasi P, Percoco G, Ferrari R. A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. International Journal of Cardiology 2008; 128(1): 53-61 Indexing Status Subject indexing assigned by NLM MeSH Aged; Antibodies, Monoclonal /administration & Cost Control; Cost-Benefit Analysis; Drug-Eluting Stents /economics; Female; Hospital Costs; Humans; Immunoglobulin Fab Fragments /administration & Immunosuppressive Agents /administration & Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction /mortality /therapy; Platelet Aggregation Inhibitors /administration & Prospective Studies; Sirolimus /administration & Statistics, Nonparametric; Stents /economics; Treatment Outcome; Tyrosine /administration & derivatives /economics; dosage; dosage; dosage; dosage /analogs & dosage /economics; dosage /economics AccessionNumber 22008101481 Date bibliographic record published 01/12/2008 |
|
|
|